1. Taiwan, Province of China Stocks

  2. •

    Industrials

  3. •

    Medical - Distribution
WeLeader Biomedical Co., Ltd.

WeLeader Biomedical Co., Ltd.

7713.TWO
WeLeader Biomedical Co., Ltd.TW flagTaipei Exchange
71.50
TWD
-0.90
- -
3.25BMarket Cap
WeLeader Biomedical Co., Ltd.
7713.TWO
(Taipei Exchange)

Recent

price

71.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
16.22
30.17
29.63
23.08
23.84
- -
24.82
Revenue per Share
1.18
3.79
4.4
3.74
4.09
- -
4.67
Basic EPS, GAAP
3.24
7.68
-10.91
2.85
2.51
- -
2.23
Free Cash Flow per Basic Share
0.79
0.8
0.28
0.73
2.3
- -
- -
Dividend per Share
5.96
11.71
14.98
15.81
16.92
- -
17.47
Book Value per Share
6.34
12.6
18.33
20.66
21.75
- -
28.14
Tangible Book Value per Share
42
28
35
41
42
- -
45
Basic Weighted Avg Shares
675
841
1,036
941
991
1,109
1,109
Sales/Revenue/Turnover
10.08
15.77
18.74
20.99
21.61
23.54
23.54
Operating Margin (%)
109
114
110
104
109
124
124
Depreciation Expense
49
106
154
152
170
209
209
Net Income, GAAP
19.91
19.54
20.12
21.32
20.91
20.09
20.09
Effective Tax Rate (%)
7.28
12.57
14.85
16.19
17.17
18.8
18.8
Profit Margin (%)
52
105
16
49
122
348
348
Working Capital
257
162
515
477
618
757
757
LT Debt
270
357
646
846
908
1,260
1,260
Total Equity
- -
15.36
15.14
10.8
10.5
10.74
10.74
Return on Invested Capital (%)
- -
17.03
17.12
12.57
12.62
13.67
13.67
Return on Capital (%)
- -
36.83
36.19
26.08
25.26
28.1
28.1
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
115
163
107
LT Borrowings
387
489
488
LT Finance Leases
225
210
268
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
2,650
3,428
3,281

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
623
760
780
Cash, Cash Equivalents & STI
199
299
335
Accounts Receivable, Net
278
307
304
Inventories
125
127
118
Total Current Liabilities
426
478
432
Payables & Accruals
- -
- -
- -
ST Debt
115
163
107
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38%
38.71%
Free Cash Flow
- -
-72.87%
-4.73%
Net Income, GAAP
- -
38.85%
22.53%
Sales/Revenue/Turnover
- -
11.19%
11.92%
Total Cash Common Dividend
- -
79.61%
60.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
248
231
- -
941
2024
235
253
256
248
991
2025
245
273
296
295
1,109

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
0.98
- -
- -
3.74
2024
1.06
1
1.06
- -
4.09
2025
0.95
1.1
1.32
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.73
2024
- -
- -
- -
- -
2.3
2025
- -
- -
- -
- -
- -
Similar Companies
EBOS Group Limited (EBO.NZ)
Health House International Limited (HHI.AX)
Shanghai Pharmaceuticals Holding Co., Ltd (601607.SS)
Nass Valley Gateway Ltd. (NVG.CN)
Accendra Health, Inc. (ACH)
Metawells Oil & Gas Inc. (KOSK)
Business
WeLeader Biomedical Co., Ltd. WeLeader Biomedical Co., Ltd. (7713.TWO) operates as an agent, wholesaler, and distributor of in vitro diagnostic products and medical devices in Taiwan. The company provides a comprehensive range of medical testing systems and equipment, including serum biochemistry integration platforms, clinical care systems, and medical information integration systems; blood gas electrolyte analyzers; urine analyzers; integrated fully automatic biochemical analyzers; fully automatic electronic luminescence immunoassay products; fully automatic modular biochemical immune assay products; TTA automated pre-processing products; POCT central laboratory products; and CCM fully automated track processing products. It serves research institutions, schools, hospitals, and laboratories primarily in Taiwan, with headquarters located at No. 80, Minzu 1st Road, 19th Floor, Kaohsiung, Taiwan, where the company was founded in 1992. In January 2024, WeLeader Biomedical listed its common stock on the Taipei Exchange (TPEX), marking its initial public offering and enhancing its access to capital markets for potential business expansion.